Dr. Chattopadhyay is a Managing Director and Equity Research Analyst covering the Biotechnology sector. He has over 12 years of relevant experience. Prior to joining Guggenheim in 2020, Dr. Chattopadhyay worked at H.C. Wainwright & Co., where he was a Managing Director covering Biotechnology. Prior to H.C. Wainwright & Co., he was a Managing Director covering Biotechnology at Janney Montgomery Scott. Dr. Chattopadhyay received his M.B.A. in Finance from Drexel University, his Ph.D., from the University of Connecticut, and his fellowship in Translation Medicine, Leukemia Service and Pharmacology at Memorial Sloan Kettering Cancer Center.
Dr. Divan is a Managing Director and Equity Research Analyst covering the Biopharma sector. Dr. Divan has more than 25 years of experience in the healthcare industry, including 15 years in Equity Research. Most recently Dr. Divan was a Senior Analyst at Mizuho Securities and prior to that he spent over a decade at Credit Suisse covering various Biopharma companies. Before transitioning to Wall Street, Dr. Divan worked in the pharmaceutical industry at Pfizer and Roche, after starting his career as an Internal Medicine physician working in an outpatient-based practice in New York City. Dr. Divan earned his B.S. from the Wharton School of Business at the University of Pennsylvania, his M.D. degree from the University of Buffalo, and his M.B.A. from the Stern School of Business at New York University.
Healthcare IT & Services
Mr. Draper is a Senior Managing Director and Equity Research Analyst covering the Healthcare IT & Services sector. He has 26 years of Wall Street research experience. Prior to Guggenheim, he worked most recently as a Managing Director at Truist Securities. Prior to Truist, he served as an Equity Research Senior Vice President at Raymond James. Mr. Draper is a CFA® Charterholder. He received his B.A. in English from the University of Virginia and his M.A. in English from the University of Georgia.
Mr. Fernandez is a Senior Managing Director and Equity Research Analyst covering the Global Biopharmaceutical and Biotechnology sectors. Mr. Fernandez has more than 20 years of experience in the healthcare industry. Prior to joining Guggenheim, he was at LEERINK Partners, where he was a Managing Director and Senior Equity Research Analyst covering Pharmaceutical and Biotechnology companies. Previously, he was a Vice President at Cowen & Company. Mr. Fernandez earned his B.A. in Chemistry from Williams College in 1995.
Dr. Schmidt is a Senior Managing Director and Equity Research Analyst covering the Biotechnology sector based in Guggenheim’s Boston office. With over a decade of experience, Dr. Schmidt joined Guggenheim from Leerink Partners in 2018 where he was a Senior Biotechnology Research Analyst. Previously, he was a healthcare analyst and consultant at Susquehanna International Group’s private equity team in San Francisco and a research fellow at Harvard University. Dr. Schmidt earned his M.S. in Biology and Ph.D. in Biochemistry at the University of Stuttgart, Germany. Dr. Schmidt was named runner-up in the 2017 Institutional Investor All-America Research Survey, Biotechnology/Mid- & Small-Cap.
Mr. Suneja is a Senior Managing Director and Equity Research Analyst covering the Biotechnology sector. Prior to joining Guggenheim, he was at SunTrust Robinson Humphrey, where he was a Managing Director and Biotechnology Analyst covering therapeutic areas in the healthcare space. Previously, he was a Vice President at Cowen & Company. He began his career at Bank of America in Corporate Banking. Mr. Suneja earned his M.B.A. from The Martin J. Whitman School of Management at Syracuse University and his B.Com in Economics and Accounting from PGDAV College at the University of Delhi in New Delhi, India.
Mr. Wallace is a Vice President and Equity Research Analyst covering the Healthcare IT & Services sector. He has over 7 years of Wall Street research experience. Prior to Guggenheim, he worked most recently as a Senior Associate at Truist Securities covering Healthcare IT & Pharmaceutical Services. Prior to Truist, he was at KeyBanc Capital Markets covering the same sectors. Mr. Wallace received his B.A. in Business Administration from Northeastern University.
Dr. Zhu is a Vice President and Equity Research Analyst covering the Biotechnology sector. Prior to joining Guggenheim, Dr. Zhu was a Life Sciences Consultant specializing in pharmaceutical market access and commercialization. Dr. Zhu received his Ph.D. in Biomedical Engineering from Rutgers, The State University of New Jersey, and his B.S. in Biological Engineering from Cornell University.
For access to our research offerings and products, please contact your Guggenheim Securities Sales representative or email GSInfo@guggenheimpartners.com. Already registered? Visit the content library on the research portal (login required).
You are now leaving this website.Guggenheim assumes no responsibility of the content or its accuracy.
Your browser does not support iframes.
2022 Guggenheim Partners, LLC. All rights reserved. Guggenheim, Guggenheim Partners and
Innovative Solutions. Enduring Values. are registered trademarks of Guggenheim Capital, LLC.
how your browser accepts cookies; please see your browser help documentation for more